Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT05491902
Other study ID # 16/NW/0705
Secondary ID
Status Terminated
Phase
First received
Last updated
Start date October 9, 2017
Est. completion date October 15, 2020

Study information

Verified date August 2022
Source University of Manchester
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Measuring the rate of cerebral protein synthesis (rCPS) may enable us to better-understand the progression of Alzheimer's Disease (AD). This study is using a new method of measuring rCPS non-invasively, and to offer new approaches to the assessment of new therapeutic strategies in clinical trials. Previous studies have established the utility of [11C]-Leucine PET to assess the rCPS. This study will use [11C]- Leucine PET to measure rCPS in AD patients versus age-matched and young healthy subjects to determine whether a measurable difference exists. The study will involve participants receiving up to two PET scans, a structural MRI scan. The PET scanning procedures will involve some withdrawal of blood samples. The ultimate goal of this proposal is to indicate new routes for treatment of AD.


Recruitment information / eligibility

Status Terminated
Enrollment 10
Est. completion date October 15, 2020
Est. primary completion date October 15, 2020
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria Patients may be included in the early onset probable AD group if they: - Are males or females between 50 and 69 years of age, inclusive, with onset of symptoms before age 65; - Meet the clinical criteria of the National Institute on Aging and the Alzheimer's Association workgroup for probable AD [25]. They have a significant cognitive impairment, Mini Mental State Examination (MMSE) score between 10 and 24 inclusive. Imaging biomarkers (hippocampal volume and cortical amyloid deposition) will be recorded for exploratory correlational analysis with PSR, but will not be used as criteria for inclusion; - Have a caregiver who can report on their mental status and activities of daily - living (ADL); - Must have capacity and be able to give informed consent. - Willing to comply with protocol and lifestyle restrictions; - Are women of childbearing potential in whom pregnancy or breast feeding has been excluded by a standard questionnaire (Appendix 3). - Understanding of English (for questionnaires); - Participant is ambulant and capable of attending a PET scan visit as an outpatient; - Participants with female partners of child-bearing potential must agree to use one of the contraception methods listed in Protocol Section 7.5.1. This criterion must be followed from after the first PET scan until after the follow-up contact; - Adequate collateral flow to the radial and ulnar arteries in both hands as determined by an Allen's test; - Body weight = 50 kg. Patients may be included in the late onset probable AD group if they: - Are males or females =70 years of age with onset of symptoms not before age 65; - Meet the clinical criteria of the National Institute on Aging and the Alzheimer's Association workgroup for probable AD [25]. They have a significant memory impairment, Mini Mental State Examination (MMSE) score between 10 and 24 inclusive. Imaging biomarkers (hippocampal volume and cortical amyloid deposition) will be recorded for exploratory correlational analysis with PSR, but will not be used as criteria for inclusion; - Have a caregiver who can report on their mental status and activities of daily living (ADL); - Must have capacity and be able to give informed consent. - Willing to comply with protocol and lifestyle restrictions; - Are women of childbearing potential in whom pregnancy or breast feeding has been excluded by a standard questionnaire (appendix).Understanding of English (for questionnaires); - Participant is ambulant and capable of attending a PET scan visit as an outpatient; - Participants with female partners of child-bearing potential must agree to use one of the contraception methods listed in Section 7.5.1. This criterion must be followed from after the first PET scan until after the follow-up contact; - Adequate collateral flow to the radial and ulnar arteries in both hands as determined by an Allen's test; - Body weight = 50 kg. Subjects may be included in the older control group if they: - Are males or females between 50 and 69 years of age, inclusive; - Do not have a history of or a current clinically significant neurologic or psychiatric disease and do not have symptoms of cognitive impairment - Have a Mini Mental State Examination (MMSE) score at screening between 27 and 30, and perform normally on a memory test including delay recall memory; - Willing to comply with protocol and lifestyle restrictions; - Are women of childbearing potential in whom pregnancy or breast feeding has been excluded by a standard questionnaire (appendix).Understanding of English (for questionnaires); - Participant is ambulant and capable of attending a PET scan visit as an outpatient; - Participants with female partners of child-bearing potential must agree to use one of the contraception methods listed in Section 7.5.1. This criterion must be followed from after the first PET scan until after the follow-up contact; - Adequate collateral flow to the radial and ulnar arteries in both hands as determined by an Allen's test; - Body weight = 50 kg. Subjects may be included in the young control group if they: - Are males or females between 18 and 25 years of age, inclusive; - Do not have a history of or a current clinically significant neurologic or psychiatric disease and do not have symptoms of cognitive impairment; - Do not have a first grade relative with early onset AD; - Have a Mini Mental State Examination (MMSE) score at screening between - 27 and 30, and perform normally on a memory test including delay recall memory; - Willing to comply with protocol and lifestyle restrictions; - Are women of childbearing potential in whom pregnancy or breast feeding has been excluded by a standard questionnaire (appendix).Understanding of English (for questionnaires); - Participant is ambulant and capable of attending a PET scan visit as an outpatient; - Participants with female partners of child-bearing potential must agree to use one of the contraception methods listed in Section 7.5.1. This criterion must be followed from after the first PET scan until after the follow-up contact; - Adequate collateral flow to the radial and ulnar arteries in both hands as determined by an Allen's test; - Body weight = 50 kg. Exclusion Criteria: - Have a history of or a current clinically significant neurologic or psychiatric disease (other than AD); - Have a current clinically significant endocrine or metabolic disease, pulmonary, renal or hepatic impairment, or cancer; - Have a clinically significant infectious disease, including Acquired Immunodeficiency Syndrome (AIDS) or Human Immunodeficiency Virus (HIV) infection; - Have a recent history of alcohol or substance abuse or dependence; - Clinically significant brain injury or abnormality, other than associated with AD; - Are women of childbearing potential who are not surgically sterile, not refraining from sexual activity, or not using reliable methods of contraception (as detailed in Section 7.5.1); - Treatment with stable doses of psychotropic medication is not prohibited. In particular, patients with AD may be on a stable dose of an anticholinesterase, memantine, neuroleptic or antidepressant, and may be taking vitamin E at the time of imaging; - Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones); - History of or suffers from claustrophobia or participant feels unable to lie flat and still on their back for a period of up to 90 minutes in the PET scanner; - Previous inclusion in a research and/or medical protocol involving nuclear medicine, PET or radiological investigations or occupational exposure in the past 12 months or greater than 10 mSv in a single year including the proposed study. Clinical exposure from which the participant receives a direct benefit is not included in these calculations; - Previous inclusion in a research and/or medical protocol involving study medication within the last 3 months; - In the opinion of the study team they are unlikely to comply with the study protocol and restrictions that it imposes. ; - Contraindications for participants undergoing an MRI scan (including but not limited to metal implants pacemakers, etc.).

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
[C11] Leucine PET scan
Each participant will receive an i.v. bolus of the PET radioligand, [11C]-Leucine (<100 µg), for each scan. [11C]-Leucine is a PET radioligand has been used and studied clinically (17-23) at micro-doses (<100 µg) with no adverse effects.
[18F] Flutemetamol PET scan
Each participant will receive an i.v. bolus of the PET radioligand, [18F]-Flutemetamol (< 10 µg), for each scan.
MRI scan
Scans will be performed on a 1.5T Philips scanner including a 3D T1-weighted scan for co-registration with PET scans and rating of hippocampal atrophy, as well as standard T1 and T2-weighted sequences for rating of white matter lesions.

Locations

Country Name City State
United Kingdom Salford Royal NHS Foundation Trust Manchester
United Kingdom Wolfson Molecular Imaging Centre (University of Manchester) Manchester

Sponsors (2)

Lead Sponsor Collaborator
University of Manchester GlaxoSmithKline

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Other Meta-analysis Meta-analysis of data collected from this study with existing literature data-sets to (1) increase the overall number of comparable data-sets which would allow for further statistical evaluation of these datasets with these higher n-numbers, and (2) to assess the consistency of data collected between groups. 2 years after completion of patient recruitment
Primary Regional changes in Protein Synthesis Rate in AD brain compared to age-matched controls A primary outcome of this study will be to determine if regional changes in PSR, as measured by [11C]-Leucine PET, in early onset AD brain are lower compared to age-matched controls. The output parameter used to determine this will be derived from the most appropriate PET pharmacokinetic model for this ligand in human. 2 years after completion of patient recruitment
Primary Regional changes in Protein Synthesis Rate in healthy controls Comparison of any regional changes in PSR from the CNS of young healthy controls with older healthy controls, will occur, to assess if there is an age-dependent decline in PSR in healthy human brain and whether its regional distribution is different from disease-related changes. 2 years after completion of patient recruitment
Secondary Regional changes in Protein Synthesis Rate in AD patients Comparison of any regional changes in PSR from the CNS of early onset AD patients compared with late onset AD patients.Assessment of amyloid deposition effect on rCPS. 2 years after completion of patient recruitment
See also
  Status Clinical Trial Phase
Completed NCT04079803 - PTI-125 for Mild-to-moderate Alzheimer's Disease Patients Phase 2
Completed NCT04044495 - Sleep, Rhythms and Risk of Alzheimer's Disease N/A
Terminated NCT03052712 - Validation and Standardization of a Battery Evaluation of the Socio-emotional Functions in Various Neurological Pathologies N/A
Recruiting NCT04520698 - Utilizing Palliative Leaders In Facilities to Transform Care for Alzheimer's Disease N/A
Active, not recruiting NCT04606420 - Can Lifestyle Changes Reverse Early-Stage Alzheimer's Disease N/A
Recruiting NCT05820919 - Enhancing Sleep Quality for Nursing Home Residents With Dementia - R33 Phase N/A
Terminated NCT03672474 - REGEnLIFE RGn530 - Feasibility Pilot N/A
Completed NCT03430648 - Is Tau Protein Linked to Mobility Function?
Recruiting NCT05557409 - A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Alzheimer's Disease Agitation Phase 3
Recruiting NCT04949750 - Efficacy of Paper-based Cognitive Training in Vietnamese Patients With Early Alzheimer's Disease N/A
Recruiting NCT04522739 - Spironolactone Safety in African Americans With Mild Cognitive Impairment and Early Alzheimer's Disease Phase 4
Recruiting NCT05288842 - Tanycytes in Alzheimer's Disease and Frontotemporal Dementia
Completed NCT06194552 - A Multiple Dose Study of the Safety and Pharmacokinetics of NTRX-07 Phase 1
Completed NCT03239561 - Evaluation of Tau Protein in the Brain of Participants With Alzheimer's Disease Compared to Healthy Participants Early Phase 1
Completed NCT03184467 - Clinical Trial to Evaluate the Efficacy and Safety of GV1001 in Alzheimer Patients Phase 2
Active, not recruiting NCT03676881 - Longitudinal Validation of a Computerized Cognitive Battery (Cognigram) in the Diagnosis of Mild Cognitive Impairment and Alzheimer's Disease
Terminated NCT03487380 - Taxonomic and Functional Composition of the Intestinal Microbiome: a Predictor of Rapid Cognitive Decline in Patients With Alzheimer's Disease N/A
Completed NCT05538455 - Investigating ProCare4Life Impact on Quality of Life of Elderly Subjects With Neurodegenerative Diseases N/A
Recruiting NCT05328115 - A Study on the Safety, Tolerability and Immunogenicity of ALZ-101 in Participants With Early Alzheimer's Disease Phase 1
Completed NCT05562583 - SAGE-LEAF: Reducing Burden in Alzheimer's Disease Caregivers Through Positive Emotion Regulation and Virtual Support N/A